Kid PROOF Act of 2025
Summary
HR6396 (Kid PROOF Act) expands eligible uses of existing SUPPORT Act grants for pediatric suicide and overdose prevention but authorizes no new funding and remains in early committee stage. No measurable revenue impact on any publicly traded company.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR6396 is a scope-expansion bill with zero new funding — no revenue impact on any publicly traded company.
- 2.The bill has been stalled in committee since December 2025 with no markup activity; low probability of near-term passage.
- 3.Even if enacted, the grant reallocation is too small to move financial results for any for-profit healthcare company.
Market Implications
No actionable market implications. HR6396 is legislative noise for investors — a procedural authorization amendment with no dollar figure attached. Retail investors should not adjust positions based on this bill. If the bill progresses to a vote with a new appropriation attached, that would be a different analysis; currently, there is no market signal.
Full Analysis
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Veterans SPORT Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.